Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Investigational drug(s) / intervention(s)
transcranial electrical stimulation treatment.
transcranial electrical stimulation treatment.: Stimulation targeting the primary motor cortex, current intensity is 1-2mA, duration is 30 minutes, once daily for 5 consecutive days
Study summary
Non-invasive neurostimulation can effectively improve patients' symptoms and has shown good therapeutic efficacy in alleviating the symptoms of IIDDs (Inflammatory Immune-mediated Demyelinating Diseases). However, some patients have not achieved the desired results, which may be due to individual differences in neural responsiveness . Therefore, this study aims to assess the therapeutic effect of transcranial electrical stimulation on improving symptoms such as painful spasm in IIDDs patients, by considering both the overall characteristics of IIDDs disease symptoms and individual differences in patients. The study will explore the imaging characteristics, electrophysiological features of the disease symptoms, and their relationship with clinical manifestations, while analyzing the key factors that influence treatment efficacy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
Patients diagnosed with neuromyelitis optica spectrum disorder, multiple sclerosis, or other central nervous system inflammatory demyelinating diseases that meet the diagnostic criteria;
Numeric Rating Scale (NRS) pain score ≥4;
Age between 18 and 65 years, regardless of gender;
Stable dose of immunosuppressive therapy for at least one month;
EDSS score ≤6;
Right-handed;
Agree to participate and sign the informed consent form.
Exclusion Criteria:
A history of relapse within the past month;
Recent medication adjustments or treatment with modified electroconvulsive therapy, transcranial magnetic stimulation, or other neurostimulation techniques within the past month;
Participation in any other clinical trial within the past month or currently participating in another clinical trial;
Presence of cochlear implants, pacemakers, or implanted stimulators in the brain;
Skin integrity at the electrode placement site is compromised, or allergy to electrode gel or adhesive;
A history of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections;
Pregnant or breastfeeding women, or those planning to become pregnant in the near future;
A score of ≥3 on item 3 (suicide item) of the HDRS-17, or a history of severe psychiatric disorders;
Presence of severe or unstable organic diseases;
Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, EEG, and imaging data collection;
Any other situation deemed unsuitable for participation in the study by the investigator.
Primary outcome measure(s)
Visual Analog Scale — From enrollment to the end of treatment at 1 month VAS Score (Visual Analog Scale) is a commonly used tool to assess pain intensity. It usually consists of a line marked with "no pain" (0 points) and "worst possible pain" (such as 0-100 points). The patient marks their level of pain on the line to provide a score. The advantage of the VAS is its simplicity, clarity, and ease of use for patients.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.